ReviewFrontiers in medicine2020
Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Early Versus Later Anticoagulation for Acute Ischemic Stroke in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.Journal of arrhythmia · 2026Article
- Bridging the Gaps in Atrial Fibrillation Management in the Emergency Department.Journal of cardiovascular development and disease · 2025Review
- Association of Body Mass Index with Echocardiographic Parameters and Incidence of Left Atrial Thrombus or Spontaneous Echo Contrast in Patients with Nonvalvular Atrial Fibrillation: A Cross-Sectional Study.Reviews in cardiovascular medicine · 2025Article
- Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation at a tertiary care hospital in Thailand.Exploratory research in clinical and social pharmacy · 2024Article
- Assays for Monitoring Apixaban and Rivaroxaban in Emergency Settings, State-of-the-Art Routine Analysis, and Volumetric Absorptive Microsamples Deliver Discordant Results.Diagnostics (Basel, Switzerland) · 2024Article
- Management of cerebral amyloid angiopathy and atrial fibrillation: We are still far from precision medicine.World journal of cardiology · 2024Review
- Role of a National Health Service Electronic Prescriptions Database in the Detection of Prescribing and Dispensing Issues and Adherence Evaluation of Direct Oral Anticoagulants.Healthcare (Basel, Switzerland) · 2024Article
- The Association between Coagulation and Atrial Fibrillation.Biomedicines · 2024Review
- Study Design of a Brazilian Observational Study of Edoxaban in Patients with Atrial Fibrillation (EdoBRA).Arquivos brasileiros de cardiologia · 2024Observational
- Safety and efficacy of percutaneous atrial appendage closure followed by antiplatelet therapy in a high-risk population: single-center experience with a WATCHMAN device.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2023Article
- Management and Anticoagulation Treatment of Non-Valvular Atrial Fibrillation in Elderly Patients: The Dali Study.International journal of general medicine · 2023Article
- Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Review
- Stroke, Thrombosis, Bleeding and Addiction to Anticoagulants in the Context of Course Therapy: A Pharmacologic Perspective.Reviews in cardiovascular medicine · 2022Article
- Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy.Physiological reports · 2021Article
- Application of computed tomographic angiography and echocardiography in predicting left atrial appendage thrombosis in patients with non-valvular atrial fibrillation.Cardiovascular journal of AfricaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulation therapy is an important method of preventing stroke in individuals with atrial fibrillation (AF). Atrial fibrillation is a quivering or irregular heartbeat that can lead to blood clots, stroke, heart failure, and other heart-related complications. Clinical guidelines on AF consistently recommend long-term oral warfarin to treat valvular atrial fibrillation (VAF). However, due to varying risks of blood clots and stroke associated with different types of non-valvular atrial fibrillation NVAF, it is unclear whether direct oral anticoagulant (DOAC) can replace warfarin. Despite a recent increase in evidence on the effectiveness and the importance of anticoagulant therapy in preventing thromboembolic events associated with NVAF, clinical prevention strategies remain complex. Given the complexities associated with clinical use of anticoagulants for patients with NVAF, this review aims to offer guidance on patient anticoagulant use based on current available evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.